ArticleMedicine2026
AA amyloidosis with multiorgan involvement secondary to severe hidradenitis suppurativa: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSecondary (amyloid A [AA]) amyloidosis is a rare but serious systemic complication of chronic inflammatory disorders. Hidradenitis suppurativa (HS) represents an uncommon cause, with approximately 20 cases reported, usually associated with severe, extensive, or long-standing disease. PATIENT CONCERNS: A 67-year-old man with severe anogenital HS (Hurley stage III), partially controlled with off-label ustekinumab, developed progressive lower-limb edema, dyspnea, distal limb hypesthesia, and weakness, eventually requiring a wheelchair. DIAGNOSES: Laboratory investigations revealed persistently elevated inflammatory markers, severe hypoalbuminemia (16.4 g/L), nephrotic-range proteinuria (14 g/24 hours), and bilateral pleural effusions. Cardiac assessment showed increased left ventricular wall thickness, low QRS voltage on electrocardiography, and preserved systolic function, while neurological studies demonstrated severe axonal sensorimotor polyneuropathy. Renal biopsy showed Congo red-positive deposits with apple-green birefringence and positive immunohistochemical staining for amyloid A, confirming AA amyloidosis.
interventionsTreatment included systemic corticosteroids, initiation of secukinumab (anti-interleukin-17A), intravenous ertapenem as induction therapy for severe HS, angiotensin-converting enzyme inhibitors, nutritional support, diuretics, and prophylactic anticoagulation. OUTCOMES: Despite a decrease in inflammatory markers and a partial reduction in nephrotic-range proteinuria, severe hypoalbuminemia and refractory anasarca persisted. The patient died approximately 5 to 6 weeks after diagnosis because of complications related to advanced systemic disease. LESSONS: This case illustrates that persistent systemic inflammation may occur in patients with severe or refractory HS despite apparent clinical stability of skin lesions. Although AA amyloidosis remains a rare complication, unexplained proteinuria or progressive hypoalbuminemia in selected high-risk patients should prompt consideration of AA amyloidosis to allow timely diagnostic evaluation before irreversible organ damage develops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.